Keywords: China, Liver cancer, Hepatocellurla carcinoma, Decision Resources, Bayer, Nexavar
China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
Article | 09 September 2010
Sales of therapies to treat hepatocellular carcinoma (HCC) in China will nearly triple from $53 million in 2009 to $144 million in 2014. Fueling ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
